Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

RedHill Biopharma (RDHL) Leases (2019 - 2025)

RedHill Biopharma has reported Leases over the past 7 years, most recently at $1.1 million for Q4 2025.

  • Quarterly Leases rose 250.0% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 250.0% year-over-year, with the annual reading at $1.1 million for FY2025, 250.0% up from the prior year.
  • Leases was $1.1 million for Q4 2025 at RedHill Biopharma, up from $163000.0 in the prior quarter.
  • Over five years, Leases peaked at $7.7 million in Q1 2022 and troughed at $163000.0 in Q2 2025.
  • The 5-year median for Leases is $4.2 million (2021), against an average of $3.7 million.
  • Year-over-year, Leases crashed 85.22% in 2023 and then soared 250.0% in 2025.
  • A 5-year view of Leases shows it stood at $3.7 million in 2021, then soared by 83.29% to $6.7 million in 2022, then crashed by 85.22% to $989000.0 in 2023, then tumbled by 69.46% to $302000.0 in 2024, then soared by 250.0% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for RDHL's Leases are $1.1 million (Q4 2025), $163000.0 (Q2 2025), and $302000.0 (Q4 2024).